MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3

Chuan He Yang1, Junming Yue1, Susan R Pfeffer1

  • 1From the Departments of Pathology and Laboratory Medicine and the Center for Cancer Research, University of Tennessee Health Science Center, Memphis, Tennessee 38163 and.

Insights

MicroRNA miR-21 is overexpressed in glioblastoma multiforme (GBM), driving tumor growth. Targeting miR-21 or increasing its target, insulin-like growth factor-binding protein-3 (IGFBP3), may improve GBM patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Glioblastoma multiforme (GBM) remains a lethal brain cancer with poor patient survival despite standard treatments.
  • MicroRNA miR-21 is recognized as an oncogene implicated in various human cancers.
  • Understanding miR-21's role in GBM is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To investigate the role of miR-21 in glioblastoma multiforme (GBM) pathogenesis.
  • To identify novel miR-21 target genes involved in GBM.
  • To explore the therapeutic potential of targeting miR-21 or its downstream effectors.

Main Methods:

  • Microarray analysis to identify novel miR-21 targets in GBM.
  • In vitro cell proliferation assays and in vivo xenograft models to assess tumor formation.
  • Quantitative analysis of miR-21 and IGFBP3 expression in patient tumor samples.

Main Results:

  • miR-21 is overexpressed in GBM tissues and cell lines, correlating inversely with patient survival.
  • Knockdown of miR-21 inhibited GBM cell proliferation and tumor growth in vivo.
  • Insulin-like growth factor-binding protein-3 (IGFBP3) was identified as a novel tumor suppressor target of miR-21.
  • Overexpression of IGFBP3 suppressed glioma cell proliferation and tumor xenograft formation.

Conclusions:

  • The oncogenic miR-21 down-regulates the tumor suppressor IGFBP3 in human glioblastoma.
  • Targeting the miR-21/IGFBP3 axis presents a promising therapeutic strategy for GBM.